Arthur M.F. Yee, MD, PhD; Mark B. Pochapin, MD
Yee AM, Pochapin MB. Treatment of Complicated Sarcoidosis with Infliximab Anti–Tumor Necrosis Factor-α Therapy. Ann Intern Med. 2001;135:27-31. doi: 10.7326/0003-4819-135-1-200107030-00010
Download citation file:
Published: Ann Intern Med. 2001;135(1):27-31.
Tumor necrosis factor-Î± (TNF-Î±) may have an important role in the clinical exacerbation of sarcoidosis.
To treat sarcoidosis with infliximab, a chimeric humanâ€“murine antiâ€“human TNF-Î± monoclonal antibody.
U.S. academic medical center.
A 72-year-old woman with sarcoidosis presenting with severe protein-losing enteropathy, hypoalbuminemia, and proximal myopathy who had not responded adequately to corticosteroid therapy and whose clinical course was further complicated by acute tubular necrosis and renal failure requiring long-term hemodialysis.
Intravenous infusion of infliximab, 5 mg/kg of ideal body weight; infusion was repeated at 2 and 6 weeks.
Clinical response of enteropathic and myopathic symptoms and serum albumin level.
Enteropathic and myopathic symptoms resolved after infliximab therapy, and the serum albumin level also improved. However, the clinical course was complicated by the development of a hypercoagulable state associated with circulating anticardiolipin antibodies, which prompted discontinuation of infliximab therapy.
Infliximab therapy was successful in a patient with sarcoidosis. Tumor necrosis factor-Î± may be an important mediator of clinical disease in sarcoidosis and could be an attractive target for therapeutic intervention. However, infliximab may cause adverse effects associated with cytokine cascade manipulation.
Learn more about subscription options.
Register Now for a free account.
Gastroenterology/Hepatology, Nephrology, Obesity, Renal Replacement Therapy, Acute Kidney Injury.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only